Please login to the form below

Not currently logged in
Email:
Password:

Axovant poaches Allergan’s and Teva’s chief medical and science officers

Gavin Corcoran and Michael Hayden join the biopharma

Gavin and MichaelClinical stage biopharmaceutical group Axovant has appointed Gavin Corcoran as its new executive vice president of research and development.

Corcoran’s career history has seen him supervise drug development across multiple therapeutic areas including neurology and psychiatry.

Most recently, Corcoran served as chief medical officer at Allergan and before that he was Actavis’ chief medical officer.

Throughout his career he has served in numerous roles for Celgene, Amgen, Schering-Plough and Bayer.

Corcoran said: “I look forward to working closely with the senior management team to bring new investigational medicines into the portfolio as we build upon Axovant’s capabilities in research and development.

“We have a wonderful opportunity to develop life-changing medicines for patients with CNS diseases.

“I am also eager to leverage the Roivant platform to accelerate the development of Axovant’s pipeline.”

Meanwhile, Teva’s former chief scientific officer Michael Hayden will also join Axovant, serving as its chairman of the scientific advisory board.

Prior to his time at Teva as its president of global research and development and chief scientific officer, Hayden founded multiple biotechnology companies including Aspreva Pharmaceuticals.

Pavan Cheruvu, chief executive officer, Axovant, said: “Since starting as CEO in February, I have been focused on transforming Axovant into a leaner organisation, introducing heightened standards of quality and excellence throughout the business, and establishing a new pipeline strategy.

“We are now poised for growth, and I am excited to have Gavin and Michael join us as we look toward expanding our pipeline in the coming months.”

5th June 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics